However, despite the clinical success of ICIs reported above, most NSCLC patients, treated with a single anti PD-1/PD-L1 agent still fail to initially respond to treatment (primary resistance) or experience disease progression after an initial response (acquired resistance). The gene discussed is CD274; the disease is non-small cell lung carcinoma.